Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells.

Tani, K; Nakazaki, Y; Hase, H; Takahashi, K; Azuma, M; Ohata, J; Kitamura, R; Komine, F; Oiwa, M; Masunaga, A; Maekawa, T; Satoh, N; Adachi, D; Soda, Y; Machida, U; Endo, M; Yamazaki, T; Watari, K; Tojo, A; Yamashita, N; Tomikawa, S; Eriguchi, M; Hamada, H; Wakumoto, Y; Hanazawa, K; Okumura, K

Tani, K; Nakazaki, Y; Hase, H; Takahashi, K; Azuma, M; Ohata, J; Kitamura, R; Komine, F; Oiwa, M; Masunaga, A; Maekawa, T; Satoh, N; Adachi, D; Soda, Y; Machida, U; Endo, M; Yamazaki, T; Watari, K; Tojo, A; Yamashita, N; Tomikawa, S; Eriguchi, M; Hamada, H; Wakumoto, Y; Hanazawa, K; Okumura, K.

Afiliación

Tani K; Institute of Medical Science, University of Tokyo, Japan. taniken@ims.u-tokyo.ac.jp

Cancer Chemother Pharmacol ; 46 Suppl: S73-6, 2000.

Article en En | MEDLINE | ID: mdl-10950152

RESUMEN

There is no effective treatment for patients with stage IV renal cell cancer (RCC), although the introduction of new therapy is imminent. Cancer gene therapy is currently considered to be one of the most promising therapeutic modalities in the field of cancer treatment. Based on the results of animal studies, vaccination using autologous granulocyte-macrophage colony-stimulating factor-transduced renal cancer cells appears promising. Before initiating a clinical study using an ex vivo gene-transduced autologous cell vaccine-based immunogene therapy for RCC in Japan, in 1992 we initially planned a Japanese version of a clinical protocol in collaboration with a US group. In 1993, the original protocol was refined. We performed five preclinical qualification studies using RCC nephrectomy specimens from patients in 1997, and the results showed that preparation of RCC cells for autologous vaccines at the Clinical Cell Technology Facility, Research Hospital of the Institute of Medical Science, University of Tokyo, was feasible. Subsequently in August 1998, the Ministry of Health and Welfare and the Ministry of Education, Science, Culture, and Sport approved our clinical protocol. We have recruited two patients with stage IV RCC to our study so far. Here we report the background to the initiation of cancer gene therapy in Japan.

Asunto(s)

Carcinoma de Células Renales/terapia; Terapia Genética/métodos; Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética; Factor Estimulante de Colonias de Granulocitos y Macrófagos/inmunología; Neoplasias Renales/terapia; Adulto; Anciano; Vacunas contra el Cáncer/genética; Vacunas contra el Cáncer/inmunología; Vacunas contra el Cáncer/uso terapéutico; Carcinoma de Células Renales/inmunología; Carcinoma de Células Renales/patología; Femenino; Vectores Genéticos; Humanos; Neoplasias Renales/inmunología; Neoplasias Renales/patología; Masculino; Persona de Mediana Edad; Estadificación de Neoplasias; Retroviridae/genética; Transducción Genética

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Terapia Genética / Factor Estimulante de Colonias de Granulocitos y Macrófagos / Neoplasias Renales Tipo de estudio: Guideline Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Año: 2000 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Alemania

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links